 Viatris Inc NASDAQ: VTRS reported Q1 FY22 sales of 4.18 billion, down 5 YY -1 on an operational basis, below the consensus of 4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist. 